(Q51088241)

29 March 2018

title

Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. (English)

1 reference

29 March 2018

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Saeed Rezaee

2

0 references

author name string

Ali-Akbar Golabchifar

1

1 reference

29 March 2018

Ardeshir Ghavamzadeh

3

1 reference

29 March 2018

Kamran Alimoghaddam

4

1 reference

29 March 2018

Nahid Mobarghei Dinan

5

1 reference

29 March 2018

Mohammad-Reza Rouini

6

1 reference

29 March 2018

publication date

10 May 2014

1 reference

29 March 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

29 March 2018

volume

74

1 reference

29 March 2018

issue

1

1 reference

29 March 2018

page(s)

85-93

1 reference

29 March 2018

https://scigraph.springernature.com/pub.10.1007/s00280-014-2473-1

exact match

0 references

cites work

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Relationship of serum imatinib trough level and response in CML patients: long term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Forecasting individual pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Balanced designs in longitudinal population pharmacokinetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2473-1

10.1007/S00280-014-2473-1

21 January 2018

Identifiers

DOI

1 reference

29 March 2018

1 reference

29 March 2018